Clinical trial NCT05337189: A Multicenter Clinical Trial of Urine DNA Testing for Bladder Cancer in China
Official title: A Multicenter, Single-blind, Observational Clinical Trial of URISAFE
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Bladder Cancer
Urocystitis
Urinary Bladder Stone
Urothelial Carcinoma
Keywords: Bladder Cancer
Urine DNA Test
Gene Methylation Biomarkers
Multigene Methylation Detection
Cancer Screening
Urothelial Carcinoma
Lead sponsor: Creative Biosciences (Guangzhou) Co., Ltd.
Sponsor class: INDUSTRY
Collaborators: name: Guangzhou Xiangkang Medical Research Co., Ltd.
First posted: 2022-04-20
Enrollment: 482
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects without age limit, regardless of gender or region, and those who meet the inclusion criteria for this clinical trial, are eligible to enroll at the designated clinical sites. 482 subjects are targeted to enroll.

Brief summary: The primary objective of this study is to assess the safety and effectiveness of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) for help diagnose bladder cancer by comparing with clinical standard method (includes medical imaging (MRI, CT, etc.), cystoscopy, pathological examination).

Detailed description: In this clinical trial, the testing kit to be evaluated is a Human Multigene Methylation Detection Kit (Fluorescent PCR Method), which is intended to qualitatively detect methylation levels of multiple genes in human urine specimen in vitro by Fluorescent PCR Method, and the standard method used in clinical diagnostic includes medical imaging, cystoscopy, pathological examination.

Subjects will provided urine specimen as required for the evaluation of the testing kit followed by a examination of standard method. Technical personnel who conduct the evaluation of the testing kit will remain blinded to the results of the clinical diagnosis.

The results of the testing kit will be compared with the standard method, and the effectiveness of the Human Multigene Methylation Detection Kit (Fluorescent PCR Method) for bladder cancer detection under normal clinical use will be assessed through statistical analysis.

Eligibility criteria: Inclusion Criteria:

* Subject must meet all three of the following criteria to be eligible for the study:

  1. Who without age and gender limit, and is participating voluntarily and willing to sign Informed Consent Form;
  2. Who is willing to undergo or has completed medical imaging and/or cystoscopy and/or pathological examination;
  3. Any subject who is required to meet any of the following conditions:

     1. Who is diagnosed with or suspected of bladder cancer.
     2. Who has high risk factors for bladder cancer (such as engaged in contact with aromatic amines, dyes, rubber, aluminum, leather and other occupations, schistosomiasis infection, family genetic history, smoking, drinking, etc.).
     3. Who has hematuria symptoms (such as cystitis, stones, etc.).
     4. Who has other diseases that can be easily confused with bladder cancer.

Exclusion Criteria:

* Subject with any of the following conditions shall be excluded:

  1. Who has undergone surgery or chemoradiotherapy.
  2. Who has other conditions that the investigator considers inappropriate to participate in this clinical trial.

Primary outcomes:
measure: Sensitivity
timeFrame: One year
measure: Specificity
timeFrame: One year
measure: Consistency Rate
timeFrame: One year
measure: Kappa Coefficient
timeFrame: One year
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Cancer Hospital
state: Beijing
Study officials:
affiliation: Peking University Cancer Hospital & Institute
name: Peng Du, PhD
role: PRINCIPAL_INVESTIGATOR
References: